Log in to search using one of your social media accounts:

 

Multiplex Testing for Rare Mutations_ What Are the Potential Benefits_ [720p]
Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing. Author: cancergrace Added: 05/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 19, 2018 Category: Cancer & Oncology Source Type: podcasts

ALK Rearrangements_ What Are They, and Who Has Them_ [720p]
Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them. Author: cancergrace Added: 05/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 19, 2018 Category: Cancer & Oncology Source Type: podcasts

ROS-1 Rearrangements_ What Are They_ [720p]
Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment. Author: cancergrace Added: 05/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 19, 2018 Category: Cancer & Oncology Source Type: podcasts

Upcoming results from clinical trials for treating relapsed, low grade lymphoma
Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks about the clinical trials with results being released soon for the treatment of low grade lymphoma. Trials... Author: VJHemOnc Added: 05/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Increasing the effectiveness of ALL therapies
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Ho... Author: VJOncology Added: 05/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Minimal residual disease: a key determinant of ALL treatment response
Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is now considered to be an equal, or greater, marker in predicting patient outcomes. MRD can aid in tailoring therapies a... Author: VJOncology Added: 05/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements [720p]
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements. Author: cancergrace Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Safety Lead-In from the Beacon Study 48% Overall Response Rate
Scott Kopetz, M.D., Ph.D., FACP, discusses Safety Lead-In from the Beacon Study 48% Overall Response Rate Author: Cancer-News Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Less Predictable Alternate BRAF Mutations Not all BRAF mutations are the same
Scott Kopetz, M.D., Ph.D., FACP, explains Less Predictable Alternate BRAF Mutations Not all BRAF mutations are the same. Author: Cancer-News Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Get Patients into Clinical Trial Sooner than Later Start with aggressive cytotoxic backbone
Scott Kopetz, M.D., Ph.D., FACP, discusses Getting Patients into Clinical Trial Sooner than Later Start with aggressive cytotoxic backbone Author: Cancer-News Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Rare Clones of KRAS Mutant Cells Able to identify resistant clones
Scott Kopetz, M.D., Ph.D., FACP, explains the Rare Clones of KRAS Mutant Cells Able to identify resistant clones Author: Cancer-News Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

BRAF V600E Mutation BRAF with EGFR Provided Synergy
Scott Kopetz, M.D., Ph.D., FACP, explains BRAF V600E Mutation BRAF with EGFR Provided Synergy. Author: Cancer-News Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Improving response to ALL therapies
Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, discusses the novel and interesting approaches for first-line therapy, in acute lymphoblastic leukemia... Author: VJOncology Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Challenges with the identification of ALL subtypes
Finding the right treatment for a specific subset of acute lymphoblastic leukemia (ALL) requires a correct diagnosis, but there are many challenges that clinicians face when trying to implement precis... Author: VJOncology Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Current understandings of ALL approaches
Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, provides an overview of his talk presented at the 2018 European School of Hematology (ESH) Clinical Up... Author: VJOncology Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Overcoming the issues with clinical trial recruitment
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the importance of collaborating with other trial groups that are focusing on acute leukemias by joining efforts with o... Author: VJOncology Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Midostaurin: the first drug to receive approval for AML since 2000
Midostaurin is a tyrosine kinase inhibitor that has been newly approved for the treatment of acute myeloid leukemia (AML). In this interview, Arnold Ganser, MD, from the Hannover Medical School, Hanno... Author: VJOncology Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Finding the right targets for CAR T-cell therapy in AML
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, expla... Author: VJOncology Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

From bench to the bedside: understanding the genetic changes in AML
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the research carried out by some of his former mentees that identified the IDH1 mutation as a novel therapeutic target... Author: VJOncology Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

The devastating effects of relapsed or refractory AML
Dealing with patients with refractory acute myeloid leukemia (AML) or with those who have relapsed, is challenging, and stem cell transplantation is one of the few therapies that can be offered in the... Author: VJOncology Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany talks about his experience of the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest,... Author: VJOncology Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Hyperprogressive disease in lung cancer
Hyperprogressive disease is a new phenomenon observed in patients treated with anti-PD-1/PD-L1 immunotherapy, characterized by accelerated tumor growth. Interestingly, hyperprogressive disease can occ... Author: VJHemOnc Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Key findings of the ALEX study: Improved therapeutic options for ALK-positive NSCLC
The key findings of the anaplastic lymphoma kinase-positive non-small cell lung cancer (ALEX) study (NCT02075840) has established alectinib as a key treatment compared with crizotinib. In this talk, S... Author: VJHemOnc Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Outcomes of the study combining necitumumab and abemaciclib in patients with NSCLC
Benjamin Besse, MD, PhD from the Institute Gustave Roussy, Villejuif, France, discusses the outcomes of the recent phase 1b study of necitumumab in combination with abemaciclib in patients with stage ... Author: VJHemOnc Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Promising treatment options for relapsed, low grade lymphoma
The 2017 American Society of Hematology (ASH) Annual Meeting, in Atlanta, GA, was an exciting event with results from multiple clinical trials being presented. Here, Nathan Fowler, MD, from the Univer... Author: VJHemOnc Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC [720p]
Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib... Author: cancergrace Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

CNS Disease in ALK-Positive NSCLC_ Monitoring and Systemic vs. Radiation Therapy [720p]
Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy. Author: cancergrace Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

A Conversation with Joan Lunden: Three Takeaways
Journalist, author and television host Joan Lunden sat down with COA executive director Ted Okon to discuss her latest book "Had I Known: A Memoir of Survival." Here she discusses key things readers s... Author: coa Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

People Helping People: Scott Hamilton on the Cancer Care Team
Scott Hamilton discusses the importance of the health care industry and everyone on the cancer care team. Author: coa Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

What is 340B?
COA Cancer Policy Minute with Ted OkonThis Cancer Policy Minute video is part of Community Oncology TV. Author: coa Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Pharmacy Benefit Managers (PBMs): Abusive Middlemen
COA Cancer Policy Minute with Ted Okon Author: coa Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

What is Community Oncology?
Did you know that the majority of Americans battling cancer receive their care in what is known as a community oncology practice? Author: coa Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

CPAN: Making a Difference
COA Patient Advocacy Network (CPAN) advocates talk about what being a part of CPAN means to them. Author: coa Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

The Price of Prescription Drugs: More Complicated Than You Think
COA Cancer Policy Minute with Ted Okon.This Cancer Policy Minute is part of the Community Oncology TV series. Author: coa Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Spotlight on Cancer Care: Always Looking Forward
Community oncology practice New England Cancer Specialists (NECS) is always looking forward, providing high quality, data-driven, low cost cancer care. Author: coa Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Spotlight on Cancer Care: Going the Extra Mile for Patients
Community oncology practices like Augusta Oncology take care of the whole patient, from diagnosis and treatment to social and financial issues. Author: coa Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Celebrity Mark Herzlich & Ted Okon On Fighting Cancer
NFL linebacker and Super Bowl champion Mark Herzlich of the New York Giants sat down with with COA executive director Ted Okon. Here he talks about his cancer journey and advice for others fighting ca... Author: coa Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Mark Herzlich: Set A Goal
NFL linebacker and Super Bowl champion Mark Herzlich of the New York Giants discusses how he created a team of caregivers, doctors, nurses, family, and friends who were there for him when battling can... Author: coa Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Timing of Second Generation ALK Inhibitors_ First Line vs. Treatment after Acquired Resistance [720p]
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib. Author: cancergrace Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Platinum-Based Chemo Doublets_ Backbone for NSCLC Treatment [720p]
Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients. Author: cancergrace Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 16, 2018 Category: Cancer & Oncology Source Type: podcasts

What is the Role of Bevacizumab in Stage IV NSCLC_ [720p]
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC. Author: cancergrace Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Histology-Specific Regimens - Squamous [720p]
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology Author: cancergrace Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Histology-Specific Recommendations - Large-Cell Neuroendocrine [720p]
Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology. Author: cancergrace Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Lurbinectedin Focus - Small Cell Lung Cancer Virtual Roundtable
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing Cancer Education leads this section on new data co... Author: Cancer-Roundtables Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Immunotherapy - Small Cell Lung Cancer Virtual Roundtable
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing Cancer Education leads this section on immunothera... Author: Cancer-Roundtables Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Small Cell Lung Cancer Virtual Roundtable - ROVA-T
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing Cancer Education leads this section on ROVA-T of a... Author: Cancer-Roundtables Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Small Cell Lung Cancer Virtual Roundtable
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing Cancer Education leads a roundtable discussing newly r... Author: Cancer-Roundtables Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Managing rare post-transplant complications: thrombotic microangiopathy
Thrombotic microangiopathy (TMA) is a rare complication that may arise post-transplant in patients, however, incidence of TMA has increased in recent years with no clear reason. Speaking at the 2018 E... Author: VJHemOnc Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Selecting the ideal donor for a stem cell transplant patient
The complications in blood and marrow transplantation can be serious with rapid onset, therefore ideal donor matching is crucial in minimizing complications. In this talk, Enric Carreras, MD, PhD, fro... Author: VJHemOnc Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Highlights from the successful 2018 EBMT annual meeting
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, discusses th... Author: VJHemOnc Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 15, 2018 Category: Cancer & Oncology Source Type: podcasts